<style face="normal" font="default" size="100%">755 DEKA-1 a dose-finding Phase 1 trial: observing safety and biomarkers using DK2<sup>10</sup> (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors failing systemic therapy</style>

Drupal-HighWire